Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3699-3705

  Nakaigawa, Noboru ^a   Yao, Masahiro ^a   Baba, Masaya ^a   Kato, Shingo ^a   Kishida, Takeshi ^a   Hattori, Keiko ^a   Nagashima, Yoji ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; NERVE CELL ADHESION MOLECULE; SCATTER FACTOR RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL DENSITY; GENE REPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; KIDNEY NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33645731190     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0617     Document Type: Article

References (54)

1. Javidan J, Stricker HJ, Tamboli P, et al. Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999;162:1277-81.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
3. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
4. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res 2004;10:6347-525.
5. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
6. Gnarra J, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
7. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
8. Lonergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-41.
9. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997;94:2156-61.
10. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999;96:12436-41.
11. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
12. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-33.
13. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41.
14. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
15. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
16. Baba M, Hirai S, Kawakami S, et al. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. Oncogene 2001;20:2727-36.
17. Cohen C, McCue PA, Derose PB. Histogenesis of renal cell carcinoma and renal oncocytoma. An immunohistochemical study. Cancer 1988;6:1946-51.
18. Thoenes W, Storkel S, Rumpelt HJ, Moll R. Cytomorphological typing of renal cell carcinoma-a new approach. Eur Urol 1990;18 Suppl 2:6-9.
19. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
20. Naldini L, Weidner KM, Vigna E. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78.
21. Bardelli A, Longati P, Gramaglia D, Stella MC, Comoglio PM. Gabi coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 1997;15:3103-11.
22. Gherardi E, Stoker M. Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cell 1991;3:227-32.
23. Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol 1997;158:724-8.
24. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
25. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
26. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50.
27. Natali PG, Prat M, Nicotra MR, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996;69:212-7.
28. Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T. Biological role of HGF/MET pathway in renal cell carcinoma. J Urol 1999;161:990-7.
29. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
30. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102:639-55.
31. 2+ binding site of uvomorulin abolish the adhesive function. Cell 1990;63:1033-8.
32. Pokutta S, Herrenknecht K, Kemler R, Engel J. Conformational changes of the recombinant extracellular domain of E-cadherin upon calcium binding. Eur J Biochem 1994;223:1019-26.
33. Shimazui T, Giroldi LA, Bringuier PP, Oosterwijk E, Schalken JA. Complex cadherin expression in renal cell carcinoma. Cancer Res 1996;56:3234-7.
34. Tani T, Laitinen L, Kangas L, Lehto W, Virtanen I. Expression of E- and N-cadherin in renal cell carcinomas, in renal cell carcinoma cell lines in vitro and in their xenografts. Int J Cancer 1995;64:407-14.
35. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME. Stage- and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993;44:147-58.
36. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001;21:865-74.
37. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A 1996;93:1320-4.
38. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 1995;55:4544-8.
39. Faletto DL, Tsarfaty I, Kmiecik TE, Gonzatti M, Suzuki T, Vande Woude GF. Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene 1992;7:1149-57.
40. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991;11:1793-803.
41. Baba M, Hirai S, Yamada-Okabe H, et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 2003;22:2728-38.
42. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-93.
43. Monga SP, Mars WM, Pediaditakis P. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71.
44. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the β-catenin pathway. Mol Cell Biol 2001;21:5857-68.
45. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
46. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
47. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995;80:225-36.
48. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 1995;80:199-211.
49. Scarpino S, Cancellario d'Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 2004;202:352-8.
50. Hashigasako A, Machide M, Nakamura T, Matsumoto K, Nakamura T. Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J Biol Chem 2004;279:26445-52.
51. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
52. Mohan S, Burk RD. von Hippel-Lindau protein complex is regulated by cell density. Oncogene 2003;22:5270-80.
53. Sako Y, Kusumi A. Compartmentalized structure of the plasma membrane for receptor movements as revealed by a nanometer-level motion analysis. J Cell Biol 1994;125:1251-64.
54. Murakoshi H, Iino R, Kobayashi T, et al. Single-molecule imaging analysis of Ras activation in living cells. Proc Natl Acad Sci U S A 2004;101:7317-22.